SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

01 Jun 2026 Evaluate
The turnover soared 63.65% to Rs. 1111.20 millions for the March 2026 quarter as compared to Rs. 679.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2026 is Rs. -1.80 millions as compared to Net Loss of Rs. -123.90 millions of corresponding quarter ended March 2025 Operating profit Margin for the quarter ended March 2026 improved to 59.00% as compared to -124.80% of corresponding quarter ended March 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 1111.20 679.00 63.65 4134.90 3098.50 33.45 4134.90 3098.50 33.45
Other Income 56.00 60.90 -8.05 180.00 166.20 8.30 180.00 166.20 8.30
PBIDT 59.00 -124.80 -147.28 2.00 96.90 -97.94 2.00 96.90 -97.94
Interest 63.30 46.40 36.42 253.00 154.60 63.65 253.00 154.60 63.65
PBDT -4.30 -171.20 -97.49 -251.00 -57.70 335.01 -251.00 -57.70 335.01
Depreciation 41.80 49.10 -14.87 187.50 202.90 -7.59 187.50 202.90 -7.59
PBT -46.10 -220.30 -79.07 -438.50 -260.60 68.27 -438.50 -260.60 68.27
TAX -44.30 -96.40 -54.05 -139.70 -108.30 28.99 -139.70 -108.30 28.99
Deferred Tax -28.40 -96.40 -70.54 -123.80 -108.30 14.31 -123.80 -108.30 14.31
PAT -1.80 -123.90 -98.55 -298.80 -152.30 96.19 -298.80 -152.30 96.19
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 5.31 -18.38 -128.89 0.05 3.13 -98.45 0.05 3.13 -98.45

Panacea Biotec Share Price

537.30 11.70 (2.23%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: